Garching / Munich, Germany, April 09, 2025 – ITM, a prominent radiopharmaceutical biotech firm, has announced the election of Barbara Weber, M.D., to its Supervisory Board, effective May 01, 2025. The election took place during ITM’s Extraordinary General Meeting. Dr. Weber is currently the President, Chief Executive Officer, and Founder of Tango Therapeutics (Nasdaq: TNGX). She brings over 25 years of executive, research, and development leadership experience from biotech, venture capital, and major pharmaceutical companies, including Novartis (NYSE: NVS) and GlaxoSmithKline (NYSE: GSK). ITM’s Supervisory Board and the company as a whole are expected to greatly benefit from Dr. Weber’s extensive expertise as they continue to advance their leading Phase 3 candidate, n.c.a. 177Lu-edotreotide (ITM-11), and further develop their radiopharmaceutical pipeline and medical radioisotope manufacturing operations.
“Dr. Weber’s proven success in building transformative oncology biotech companies is a testament to her business insight and commitment to improving the lives of cancer patients. Her deep understanding of the industry and science, including her demonstrated ability to guide novel compounds from clinical trials to FDA approval, will be an invaluable asset to ITM,” stated Udo J. Vetter, Chairman of the Supervisory Board of ITM. “The expansion of our Supervisory Board and its collective knowledge ensures ITM is well-positioned to continue accelerating the growth of its radiopharmaceutical pipeline and medical radioisotope business.”
Dr. Weber is a physician-scientist with a remarkable clinical and academic background, along with significant leadership experience in global pharmaceutical development. As President, Chief Executive Officer, and Founder of Tango Therapeutics, she spearheaded the company’s transition to a publicly traded entity and the development of its precision oncology product candidates, which are based on the genetic principle of synthetic lethality. During her time as a Venture Partner at Third Rock Ventures, she led teams in the creation of new oncology drug discovery companies, including Tango Therapeutics, Neon Therapeutics (later acquired by BioNTech (Nasdaq: BNTX)), and Relay Therapeutics (Nasdaq: RLAY).
“As a physician and business executive dedicated to the fight against cancer, I recognize the significant potential of targeted radiopharmaceutical therapy to enhance the precision of oncology treatment and improve patient outcomes. I am eager to collaborate with ITM’s Supervisory Board and Leadership Team as the company prepares for an NDA submission for ITM-11 and expands its pipeline with a variety of promising alpha- and beta-emitting radioisotopes combined with innovative targeting agents,” said Dr. Weber.
Before joining Third Rock Ventures, Dr. Weber held the position of Senior Vice President, Oncology Translational Medicine at Novartis and Vice President, Oncology Discovery and Translational Medicine at GlaxoSmithKline. During her tenure, she played a vital role in leading clinical studies and securing FDA approvals for several drugs, including Zykadia®, Kisqali®, Vijoice®, and Promacta®. Dr. Weber earned her Doctor of Medicine degree from the University of Washington and has been affiliated with the University of Pennsylvania, Yale University, and the Dana-Farber Cancer Institute. She currently serves on the Board of Directors at Tango Therapeutics, Revolution Medicines Inc. (Nasdaq: RVMD), Parabilis Medicines, and Sesame Therapeutics.
About ITM Isotope Technologies Munich SE
ITM, a leading radiopharmaceutical biotech company, is dedicated to developing a new generation of radiopharmaceutical therapeutics and diagnostics for cancers that are difficult to treat. Our goal is to address the needs of cancer patients, clinicians, and our partners through excellence in development, production, and global supply. With a focus on improving patient outcomes, ITM is advancing a broad precision oncology pipeline that includes multiple Phase 3 studies, combining the company’s high-quality radioisotopes with a range of targeting molecules. By leveraging our two decades of pioneering expertise in radiopharmaceuticals, our central position in the industry, and our established global network, ITM aims to provide patients with more effective targeted treatments to improve clinical outcomes and quality of life.
ITM Contact
Corporate Communications
Kathleen Noonan/Julia Westermeir
Phone: +49 89 329 8986 1500
Email:
Investor Relations
Ben Orzelek
Phone: +49 89 329 8986 1009
Email:
Attachments
“`